Several studies show that the immunosuppressive drugs targeting the interleukin-6 (IL-6)
receptor, including tocilizumab, ameliorate lethal inflammatory responses in COVID-19 …

Background The emergence of the novel coronavirus in Wuhan, Hubei Province, China, in
December 2019 marked the synchronization of the world to a peculiar clock that is counting …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of
coronavirus disease 2019 (COVID-19). Understanding of the fundamental processes …

An improved understanding of human T cell-mediated immunity in COVID-19 is important for
optimizing therapeutic and vaccine strategies. Experience with influenza shows that …

Current scenario depicts that world has been clenched by COVID-19 pandemic. Inevitably,
public health and safety measures could be undertaken in order to dwindle the infection …

SARS‐CoV‐2 is a novel human coronavirus responsible for the Coronavirus disease 2019
(COVID‐19) pandemic. Pneumonia and acute respiratory distress syndrome are the major …

Coronavirus disease 2019 (COVID-19) outbreak has become a global pandemic. The
deleterious effects of coronavirus have prompted the development of diagnostic tools to …

Rationale: Uncontrolled inflammatory innate response and impaired adaptive immune
response are associated with clinical severity in patients with coronavirus disease (COVID …

With the worldwide spread of the novel severe acute respiratory syndrome coronavirus‐2
(SARS‐CoV‐2) resulting in declaration of a pandemic by the World Health Organization …

Abstract The coronavirus disease 2019 (COVID-19) pandemic has led to dramatic changes
in oncology practice. It is currently unknown whether programmed death 1 (PD-1) blockade …